Product Images Afluria Quadrivalent

This is a description of the AFLURIA Quadrivalent influenza vaccine for the 2022-2023 season. It is suitable for individuals aged 3 and over and has been standardized according to USPHS requirements. The vaccine contains four strains of the influenza virus grown in embryonated chicken eggs and inactivated with beta-propiolactone. Each 0.5 mL dose contains 15 mcg hemagglutinin (HA) of each of the four strains. Small quantities of polymysin, neomycin, and hydrocortisone may be present in trace amounts due to the initial stages of manufacture. The vaccine has no preservatives and doesn't contain natural rubber latex. It is stored between 2 - 8°C and must not be frozen. The package contains 10 pre-filled syringes, and the vaccine is for intramuscular injection only. The manufacturer of this vaccine is Seqirus Pty Ltd, Parkvile, VIC 3052, Australia, and it is distributed by Seqirus USA Inc., Summit, NJ 07901, USA.*

Description: This is a product information page for Afluria Quadrivalent Influenza Vaccine 2022-2023 Formula B Only. The vaccine is administered through intramuscular injection to individuals aged five and older. The package contains a 5mL multi-dose vial. The page includes NDC (national drug code) information for the product.*

This text describes the usage, dosage, and storage requirements for a medical product from Seqirus Pty Ltd. The product comes in two doses of 0.25 mL and 0.5 mL, recommended for children 6-35 months and 3 years and older. The package insert provides more information. The product should be stored between 2-8°C and not be frozen. It has been manufactured in Australia by Seqirus Pty Ltd and distributed in the USA by Seqirus USA Inc.*